$1.86
+0.01 (+0.54%)
Open$1.85
Previous Close$1.85
Day High$1.88
Day Low$1.83
52W High$3.10
52W Low$1.33
Volume—
Avg Volume806.6K
Market Cap255.46M
P/E Ratio—
EPS$-0.43
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+394.6% upside
Current
$1.86
$1.86
Target
$9.20
$9.20
$6.27
$9.20 avg
$10.38
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 21.32M | 14.17M | 53.79M |
| Net Income | -55,006,767 | -32,905,344 | 2.31M |
| Profit Margin | -258.1% | -245.2% | 4.3% |
| EBITDA | -53,592,111 | -33,840,149 | 4.13M |
| Free Cash Flow | — | — | 1.88M |
| Rev Growth | +50.5% | +50.5% | +4.8% |
| Debt/Equity | 0.32 | 0.32 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |